Market Access

European payers and health technology appraisal organizations have warned that their decision making is being increasingly hampered by evidence gaps. Some solutions may lie in the better use of existing mechanisms, such as scientific advice and managed entry agreements, while others could be introduced through the overhaul of the EU pharmaceutical legislation.

Pharma's commercial workforce is engaging with its customers in a myriad of new ways, all of them fueled by digital. These efforts must be co-ordinated, and embrace news ways of working if they are to succeed.

Offering a challenging but blossoming free market model, strong academic institutions and an excellent track record in patents, the Swiss Biotech industry is one to watch. 

China is transitioning to an economy driven by innovation and technology, with differential effects on foreign medtechs depending on their place in the value chain and type of innovation. China commentators have been updating the market.

Inaccessible price points, development risk, and a lack of diversity in gene therapy R&D all feed into the imperfect state in which the industry's newest form of innovation exists. New approaches are needed if the patient populations that need these medicines the most can benefit.

Rising Leader Christopher Jon Stokes of Eli Lilly explains how some early life lessons in the restorative powers of community has guided a distinctive career path marked by engaging widely, understanding intuitively and listening actively, all in the pursuit of forging productive human connections that strive to “meet the moment” for patients.

Russia and Ukraine had been key players in the pharma markets of Central Asian and surrounding countries before the launch of the Russian invasion into its neighbor on 24 February. Because of this, both countries are poised to give ground in this growing regional market.

Pharmaceutical leaders are responding to the many and varied challenges arising from the war in Ukraine.

With pricing pressures already creeping up in recent years, 2022 is set to see the generics industry caught in the middle as prices are further squeezed while costs continue to rise. As major players prepare to announce their first-quarter financial results, In Vivo looks at views from industry leaders on how these pressures are affecting their businesses, and how they can be expected to play out.

Compassionate use programs (CUP) are a developing field in Asian countries. In the majority of Asian states, the CU applies to Named-Patients Program (NPP). In the most countries, understanding of CUP for unapproved drugs is poor among the public, and even for professional communities. 

Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action. 

An ambitious five-year public-private partnership plans to tackle non-adherence to medicines by giving patients EU-wide access to regulator-approved digital drug information. One year in, progress has been made in creating an app that could do just this.